Related Experiment Video
Updated: Sep 24, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Molecular imaging in Parkinsonism: The essential for clinical practice and future perspectives
T Horowitz1, S Grimaldi2, J-P Azulay3
1Department of Nuclear Medicine, Public Assistance Hospitals of Marseille, Timone University Hospital, Marseille, France; Centre Européen de Recherche en Imagerie Médicale, Aix-Marseille University, Marseille, France.
Abstract:
Nuclear medicine with positron emission tomography (PET) and single photon emission computed tomography (SPECT) develops powerful tools in molecular imaging to help clinicians in the challenging diagnosis of parkinsonism. These techniques can provide biomarkers for neurodegenerative parkinsonism and to distinguish Parkinson disease (PD) from atypical parkinsonism. This review summarizes the main SPECT and PET contributions to the diagnosis of parkinsonism. We will also discuss new technologies in the field of nuclear imaging and their potential contribution to the diagnosis of parkinsonian syndromes.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Brain Imaging
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies IV: Magnetic Resonance Imaging

